Related Experiment Video
Updated: Jul 1, 2025

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Keratinocyte-derived circulating microRNAs in extracellular vesicles: a novel biomarker of psoriasis severity and
Young Joon Park1, Dong Chan Kim1, Soo-Jin Lee1
1Department of Dermatology, Ajou University School of Medicine, Ajou University Hospital, 164, World Cup-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do, 16499, South Korea.
Background:
Psoriasis is a chronic inflammatory disorder characterized by pathogenic hyperproliferation of keratinocytes and immune dysregulation. Currently, objective evaluation tools reflecting the severity of psoriasis are insufficient. MicroRNAs in extracellular vesicles (EV miRNAs) have been shown to be potential biomarkers for various inflammatory diseases. Our objective was to investigate the possibility of plasma-derived EV miRNAs as a marker for the psoriasis disease severity.
Methods:
EVs were extracted from the plasma of 63 patients with psoriasis and 12 with Behçet's disease. We performed next-generation sequencing of the plasma-derived EV miRNAs from the psoriasis patients. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to validate the level of EV miRNA expression. In situ hybridization was used to discern the anatomical location of miRNAs. qRT-PCR, western blotting, and cell counting kits (CCKs) were used to investigate IGF-1 signaling in cells transfected with miRNA mimics.
Results:
We identified 19 differentially expressed EV miRNAs and validated the top three up-and down-regulated EV miRNAs. Among these, miR-625-3p was significantly increased in patients with severe psoriasis in both plasma and skin and most accurately distinguished moderate-to-severe psoriasis from mild-to-moderate psoriasis. It was produced and secreted by keratinocytes upon stimulation. We also observed a significant intensification of IGF-1 signalling and increased cell numbers in the miR-625-3p mimic transfected cells.
Conclusions:
We propose keratinocyte-derived EV miR-625-3p as a novel and reliable biomarker for estimating the severity of psoriasis. This biomarker could objectively evaluate the severity of psoriasis in the clinical setting and might serve as a potential therapeutic target. Trial registration None.
Insights
Plasma-derived extracellular vesicle microRNAs (EV miRNAs) show promise as psoriasis severity biomarkers. Specifically, miR-625-3p, found in keratinocytes, accurately indicates psoriasis severity and may offer a therapeutic target.
Area of Science:
- Dermatology
- Molecular Biology
- Biomarker Discovery
Background:
- Psoriasis is a chronic inflammatory skin disease with insufficient objective severity assessment tools.
- Extracellular vesicle microRNAs (EV miRNAs) are emerging biomarkers for inflammatory conditions.
- Investigating plasma-derived EV miRNAs for psoriasis severity correlation is crucial.
Purpose of the Study:
- To explore plasma-derived EV miRNAs as potential biomarkers for psoriasis disease severity.
- To identify specific EV miRNAs associated with different psoriasis severity levels.
- To evaluate the clinical utility of EV miRNAs in assessing psoriasis.
Main Methods:
- Extracted extracellular vesicles (EVs) from plasma of psoriasis and Behçet's disease patients.
- Performed next-generation sequencing and qRT-PCR to analyze plasma-derived EV miRNAs.
- Utilized in situ hybridization and cell-based assays to investigate miRNA function and signaling pathways.
Main Results:
- Identified 19 differentially expressed EV miRNAs, validating top candidates.
- miR-625-3p was significantly elevated in severe psoriasis patients (plasma and skin) and distinguished severity grades.
- miR-625-3p mimic transfection increased IGF-1 signaling and cell proliferation.
Conclusions:
- Keratinocyte-derived EV miR-625-3p is a novel, reliable biomarker for psoriasis severity.
- This biomarker offers objective clinical assessment of psoriasis severity.
- EV miR-625-3p represents a potential therapeutic target for psoriasis.
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Clinical Applications of Epidermal Stem Cells

